Syngene International Ltd. Share Price

Syngene International Ltd – Bullish Momentum Strengthening

SYNGENE Syngene International is displaying strong bullish momentum following a significant recovery from its previous support zone. The stock is currently trading around ₹435, with the latest price action indicating sustained buying interest and improving market sentiment. After consolidating near the ₹360–₹380 region, the stock staged a strong upward move and has gradually reclaimed several important resistance levels. The recent bullish candles suggest that buyers are maintaining control, while the price structure indicates a potential continuation of the ongoing recovery. 🔑 Key Support Levels: ₹418.85 | ₹400.25 | ₹381.65 | ₹363.05 🚧 Key Resistance Levels: ₹437.45 | ₹456.05 | ₹474.65 | ₹493.25 📈 Technical Outlook: The stock is approaching an important resistance zone around ₹437.45. A sustained breakout above this level, supported by healthy trading volume, could strengthen the bullish setup and potentially open the way towards ₹456.05 and ₹474.65. The momentum indicators are showing positive signals, with MACD remaining in positive territory and RSI around 66.74, reflecting improving buying strength. However, the RSI is approaching the higher momentum zone, so some short-term consolidation or profit-booking cannot be ruled out. On the downside, ₹418.85 is the immediate support to monitor, followed by ₹400.25. Sustaining above these levels would help preserve the current bullish structure. Conclusion: Syngene International is showing a promising recovery with improving momentum and a positive short-term technical structure. A decisive move above ₹437.45 could provide further upside potential towards ₹456.05, ₹474.65 and eventually ₹493.25. Traders should monitor breakout confirmation and volume participation before taking fresh positions. Appropriate stop-loss discipline and risk management remain essential, particularly near the current resistance zone.

Syngene jumps 12% despite Q2 profit fall, resistance at 420

Syngene International gained 12.19% to Rs 410.85 despite a 52% fall in Q2 profit, with support at Rs 344 and resistance at Rs 420. Syngene International Limited [ SYNGENE ] gained 12.19% to Rs 410.85 on 28 October, its second straight session higher, despite a 52% fall in Q2 FY27 profit. Consolidated profit fell to Rs 32.2 crore from Rs 67.1 crore. Revenue fell 8.6% to Rs 832.7 crore from Rs 910.6 crore. The numbers improved sharply from Q1, when revenue was Rs 736 crore and the company posted a loss of Rs 9 crore. Operating EBITDA margin rose 6 percentage points to 18%. Syngene’s US biologics facility, Bayview, signed its first manufacturing agreement with a large pharma customer, which gives an underused asset a path to revenue. The stock was in a strong downtrend, about 57% below its December 2024 peak near Rs 960. The bounce came from buying near the Rs 344 low. RSI is 62.80, above its average of 48.34, so momentum has turned up. Resistance is Rs 420. Support is Rs 344. A close above Rs 420 would extend the recovery. A close below Rs 344 would resume the downtrend. Volume of 32.97 million shares helps, but follow-through is key. DISCLOSURE: I do not hold any position in this stock. This is not a recommendation to buy or sell. Investments in securities markets are subject to market risks. Read all related documents carefully before investing.

Jubilant Pharmova assigned IND AA+/Stable to ₹1,400 Cr NCDs.

JUBLPHARMA Jubilant Pharmova Limited (JUBLPHARMA) has received a credit rating assignment from India Ratings and Research Pvt Ltd. The rating is for proposed non-convertible debentures amounting to ₹1,400 crore. The instrument is Proposed Non-Convertible Debentures of ₹1,400 crore. The assigned rating is IND AA+/Stable. The rating action is Assigned. The key trigger is the assignment of an IND AA+/Stable rating for the proposed ₹1,400 crore NCD issuance, which supports the company’s funding plans without equity dilution. This reflects a favourable view of its credit profile in the specialty pharmaceuticals and CDMO space. Peers such as Syngene International, Piramal Pharma, and Divi’s Laboratories may face comparison on balance-sheet strength and debt-raising capacity. Near-term prices could see a mild positive reaction on the rating assignment and funding visibility. Risks include the final terms of the NCD issuance or any subsequent pressure on leverage metrics. Competitors listed: Syngene International, Piramal Pharma, Divi’s Laboratories.

Syngene attempts a base after a prolonged decline

SYNGENE is trading near ₹386 after an extended decline that has pushed the stock close to its recent base. The chart shows a persistent pattern of lower highs through much of the year, followed by a modest bounce from the ₹350–360 region. That rebound has improved the immediate tone, but price remains within a broader downtrend until it can recover the prior swing zones above ₹400 and ₹420. Connors RSI has lifted to about 63.99 from weaker readings, signalling that short-term price behaviour, streak momentum and the recent rate-of-change component have improved together. The reading is constructive without being in the classic overbought zone above 70. However, Connors RSI is designed to identify short-term momentum extremes; by itself, it does not overturn the larger sequence of lower highs visible on the price chart. The key support area is ₹360–350. A close below it would negate the present stabilisation and extend the lower-low pattern. On the upside, ₹400 is the first level where sellers may reappear, followed by ₹420–430, which marked earlier breakdown points. Syngene’s research-services business gives it a differentiated healthcare positioning, yet the technical work is unfinished. The constructive scenario requires the stock to defend ₹360, form higher lows, and reclaim ₹400 with follow-through. Until that sequence develops, the move from ₹350 looks like a relief bounce inside a larger corrective trend rather than a confirmed change in direction.

Innova Captab Board OKs ₹50 Cr Land Acquisition

INNOVACAP Board of Directors has accorded in-principle approval for the acquisition of land with an estimated investment of approximately ₹50 crore. The proposed land purchase forms part of the company’s strategic real estate expansion and plans for operational facility development. The Board will provide further updates once the final purchase or sale agreement is executed between the parties. This move aligns with Innova Captab’s broader growth strategy in the pharmaceutical manufacturing and CDMO space, aimed at supporting future capacity needs and strengthening its operational footprint. The in-principle clearance marks an important step towards enhancing the company’s long-term manufacturing and infrastructure capabilities. **Top stocks in the pharmaceuticals / CDMO industry:** Laurus Labs, Syngene International, and Divi’s Laboratories.

Syngene International Limited Latest Updates

SYNGENE Q1 FY27 Financial Results & Net Loss On July 29, 2026, Syngene International reported its financial results for the first quarter ended June 30, 2026 (Q1 FY27). Revenue from operations declined 15.8% year-on-year to ₹736 crore (down from ₹874.5 crore in Q1 FY26). Lower operating leverage, biologics demand adjustments, and an exceptional charge of ₹13.5 crore for employee termination benefits led to a consolidated net loss of ₹9.00 crore, compared to a net profit of ₹86.70 crore in the year-ago period. Executive Leadership Transition Effective July 1, 2026, Mr. Siddharth Mittal officially took charge as the Managing Director and Chief Executive Officer (MD & CEO) of Syngene International, succeeding Peter Bains following a planned leadership transition. Alongside the CEO transition, the company appointed new commercial leadership to accelerate client outreach across the US and European contract development and manufacturing (CDMO) markets. Balance Sheet Liquidity & Cash ReservesDespite operating headwinds in Q1 FY27, Syngene maintained a conservative capital structure with a net cash reserve of ₹1,541 crore. The strong balance sheet provides financial headroom as the company manages operating expenses and continues commercial integration for its US Bayview facility and biologics development infrastructure. Technology & Research Collaborations Syngene expanded its proprietary ***** drug discovery platform, deploying gigascale virtual screening capabilities to enhance early-stage hit-finding for global pharmaceutical clients. In clinical development, the company signed a strategic Memorandum of Understanding (MoU) with the Translational Health Science and Technology Institute (BRIC-THSTI) to collaborate on early and late-phase clinical trials and translational research.